AMT: preclinical pharmacology studies.

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Auron-Misheil-Therapy (AMT) is an investigational anti-cancer treatment combining chamomile extract with calcium, vitamins, chlorpheniramine, and human insulin.
• Preclinical evaluation is crucial to guide the clinical development of AMT for cancer therapy.

Purpose of the Study:

• To assess the preclinical anti-cancer activity and immune-modulatory effects of Auron-Misheil-Therapy (AMT).
• To identify specific cancer types most susceptible to AMT for guiding clinical trials.

Main Methods:

• AMT was tested against 56 human tumor cell lines in vitro.
• Clonogenic assays were performed on 98 patient-derived tumor xenografts.
• In vivo studies evaluated AMT's efficacy in tumor xenograft models.
• Immune stimulatory effects were assessed by measuring cytokine secretion (IL-6, TNF-alpha) in human PBMCs.

Main Results:

• AMT exhibited in vitro cytotoxic activity, with notable susceptibility in cervical cancer, glioblastoma, and colon cancers.
• The clonogenic assay indicated significant anti-cancer activity in cervical, uterine, colon, glioblastoma, leukemia, melanoma, and pancreatic cancers.
• In vivo studies showed modest activity in colon and mammary cancer xenografts.
• AMT induced IL-6 and TNF-alpha secretion in human PBMCs, indicating immune stimulatory effects.

Conclusions:

• AMT demonstrates preclinical anti-cancer activity across a range of tumor types.
• The immune stimulatory potential of AMT, alongside its anti-tumor effects, suggests a potential therapeutic role in cancer treatment.
• Further clinical investigation is warranted based on these preclinical findings.